Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 9/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406562 | 0.92 | KLK5 (0.46) | PREPFAPCMA1ACEKLK5 | |
| SCHEMBL16000759 | 0.89 | ACE (0.53) | CMA1ACEKMT2AHSD17B10 | |
| SCHEMBL13950858 | 0.89 | ACE (0.53) | CMA1ACEKMT2AHSD17B10 | |
| SCHEMBL6242739 | 0.89 | ACE (0.53) | CMA1ACEKMT2AHSD17B10 | |
| SCHEMBL2262901 | 0.89 | ACE (0.53) | CMA1ACEKMT2AHSD17B10 | |
| SCHEMBL17348387 | 0.89 | ACE (0.53) | CMA1ACEKMT2AHSD17B10 | |
| SCHEMBL13258959 | 0.88 | CMA1 (0.51) | CMA1ELANECTSLCTSBCTSK | |
| SCHEMBL17348390 | 0.88 | KLK5 (0.53) | PREPFAPCMA1ACEKLK5 | |
| SCHEMBL7311829 | 0.88 | KLK5 (0.53) | PREPFAPCMA1ACEKLK5 | |
| SCHEMBL14235324 | 0.88 | CMA1 (0.44) | PREPFAPCMA1ACEKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | PREP 21/4885FAP 44/4885CMA1 1706/4885 |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | PREP 21/4885FAP 44/4885CMA1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.